目的 探討血栓心脈寧膠囊聯(lián)合單唾液酸四己糖神經(jīng)節(jié)苷脂治療腦梗死的臨床效果。方法 收集2015年9月-2016年9月在重慶市長(zhǎng)壽區(qū)人民醫(yī)院進(jìn)行治療的腦梗死患者98例，根據(jù)治療方案的差別分為對(duì)照組（49例）和治療組（49例）。對(duì)照組患者靜脈滴注單唾液酸四己糖神經(jīng)節(jié)苷脂鈉注射液，60 mg加入生理鹽水250 mL中，1次/d。治療組在對(duì)照組的基礎(chǔ)上口服血栓心脈寧膠囊，4粒/次，3次/d。兩組患者均連續(xù)治療4周。比較治療前后兩組患者臨床療效、神經(jīng)功能缺損評(píng)分和神經(jīng)功能指標(biāo)差異。結(jié)果 治療后，對(duì)照組患者的總有效率為79.59%，顯著低于治療組的95.92%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組患者神經(jīng)功能缺損評(píng)分均明顯降低，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組上述評(píng)分改善情況顯著好于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血清神經(jīng)元特異性烯醇化酶（NSE）、血紅素氧合酶-1（HO1）、S100β水平均明顯降低，胰島素樣生長(zhǎng)因子-1（IGF-1）水平升高，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組患者上述指標(biāo)比對(duì)照組改善更顯著，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 血栓心脈寧膠囊聯(lián)合單唾液酸四己糖神經(jīng)節(jié)苷脂治療腦梗死效果顯著，可明顯改善患者神經(jīng)功能，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of Xueshuan Xinmaining Capsules combined with onosialotetrahexosylganglioside in treatment of cerebral infarction. Methods Patients (98 cases) with cerebral infarction in People's Hospital of Changshou Chongqing from September 2015 to September 2016 were divided into control (49 cases) and treatment (49 cases) groups based on different treatments. Patients in the control group were iv administered with Monosialotetrahexosylganglioside Sodium Injection, 60 mg added into 250 mL normal saline, once daily. Patients in the treatment group were po administered with Xueshuan Xinmaining Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the differences of clinical efficacy, neurological deficit score, and nerve function in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 79.59%, which was significantly lower than 95.92% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the neurological deficit scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the score in the treatment group was significantly better than that in the control group, with significant difference between two groups (P < 0.05). After treatment, the serum NSE, HO1 and S100β levels in two groups were significantly decreased, but IGF-1 level was significantly increased, and there were differences in the same group (P < 0.05). And the indexes in the treatment group were improved more significantly than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Xueshuan Xinmaining Capsules combined with onosialotetrahexosylganglioside has significant effect in treatment of cerebral infarction, and can obviously improve the neurological function, which has a certain clinical application value.